First-line nivolumab plus ipilimumab for unresectable MPM in China: a cost-effectiveness analysis.

v1

Type:Journal Article

0 views

[![NobleID](https://www.nobleid.org/api/badge/99552B1E.svg?ark=w1%2F20260523%2F99552B1E&value=id)](https://nobleid.org/work/w1/20260523/99552B1E)

ARK Inflections

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors